← Back to Search

Home Exercise for Neurodegenerative Disease

N/A
Recruiting
Led By Jennifer Keller, PT
Research Sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
For females: X-linked adrenoleukodystrophy as determined by biochemical determination, genetic testing, or pedigree analysis
Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation inclusion criterion: confirmed DARS2 mutation through genetic analysis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline 12 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trialaims to develop treatments that improve walking ability in people with neurodegenerative diseases.

Who is the study for?
This trial is for individuals with specific neurodegenerative diseases like ataxia, leukodystrophy, or those with cerebellar damage due to stroke or tumor. Participants must have a confirmed genetic mutation related to their condition, be able to stand and walk with or without support, and not have other health issues that could interfere with the exercise program.
What is being tested?
The study tests a home exercise regimen designed to improve walking abilities in people suffering from neurodegenerative diseases. It aims to create targeted therapeutic interventions tailored for these conditions.
What are the potential side effects?
Since this trial involves home exercises, side effects may include muscle soreness, fatigue, and an increased risk of falls if exercises are not performed safely.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a female diagnosed with X-linked adrenoleukodystrophy.
Select...
I have a confirmed DARS2 mutation linked to my leukoencephalopathy.
Select...
I am a male diagnosed with X-linked adrenoleukodystrophy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in NeuroQOL lower extremity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Home exerciseExperimental Treatment1 Intervention
Individually designed home exercise program
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Home exercise
2017
Completed Phase 2
~1740

Find a Location

Who is running the clinical trial?

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Lead Sponsor
90 Previous Clinical Trials
24,830 Total Patients Enrolled
Jennifer Keller, PTPrincipal InvestigatorHugo W. Moser Research Institute at Kennedy Krieger, Inc.

Media Library

Home exercise Clinical Trial Eligibility Overview. Trial Name: NCT05443906 — N/A
Neurodegenerative Disease Research Study Groups: Home exercise
Neurodegenerative Disease Clinical Trial 2023: Home exercise Highlights & Side Effects. Trial Name: NCT05443906 — N/A
Home exercise 2023 Treatment Timeline for Medical Study. Trial Name: NCT05443906 — N/A
~14 spots leftby Jul 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top